Materials and methods for treating viral infections
The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
1. A method for treating a viral influenza infection, wherein said method comprises diagnosing a subject with the viral influenza infection; and administering to the subject an effective amount of cysteamine or a salt thereof.
2. The method, according to claim 1 , wherein the subject is infected with at least one of the group consisting of influenza virus subtype H1N1, H1N2, H2N2, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N2, and H10N7.
3. The method, according to claim 2 , wherein the influenza virus subtype(s) is selected from the group consisting of avian influenza viruses, Spanish influenza viruses. Asian influenza viruses, Hong Kong influenza viruses, swine influenza viruses, equine influenza viruses, canine influenza viruses, and influenza A, B, and C viruses.
4. The method according to claim 1 , which comprises administering at least 0.1 mg of the cysteamine, or salt thereof, to the subject daily.
5. The method, according to claim 4 , which comprises administering between 2 mg to 3,000 mg of the cysteamine, or salt thereof, daily.
6. The method, according to claim 1 , wherein said cysteamine salt is cysteamine hydrochloride.
7. The method, according to claim 1 , wherein said cysteamine, or salt thereof, is taken orally, parenterally, intravenously, intramuscularly, transdermally, via buccal route, subcutaneously, or via suppository.
8. A method for reducing the severity, intensity, or duration of symptoms associated with a viral influenza infection, wherein said method comprises diagnosing a subject with the viral influenza infection; and administering to the subject an effective amount of cysteamine, or salt thereof.
9. The method, according to claim 8 , wherein the subject is infected with at least one of the group consisting of influenza virus subtype H1N1, H1N2, H2N2, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N2, and H10N7.
10. The method, according to claim 9 , wherein the influenza virus subtype(s) is selected from the group consisting of avian influenza viruses, Spanish influenza viruses, Asian influenza viruses, Hong Kong influenza viruses, swine influenza viruses, equine influenza viruses, canine influenza viruses, and influenza A, B, and C viruses.
11. The method, according to claim 8 , which comprises administering at least 0.1 mg of the cysteamine, or salt thereof, to the subject daily.
12. The method, according to claim 11 , which comprises administering between 2 mg to 3,000 mg of the cysteamine, or salt thereof, daily.
13. The method according to claim 8 , wherein the cysteamine salt is cysteamine hydrochloride.
14. The method, according to claim 8 , wherein said cysteamine, or salt thereof, is taken orally, parenterally, intravenously, intramuscularly, transdermally, via buccal route, subcutaneously, or via suppository.